Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT05765084
Title Integration of the PD-L1 Inhibitor Atezolizumab and WT1/DC Vaccination Into Platinum/Pemetrexed-based First-line Treatment for Epithelioid Malignant Pleural Mesothelioma (Immuno-MESODEC)
Acronym Immuno-MESODEC
Recruitment Recruiting
Gender both
Phase Phase Ib/II
Variant Requirements No
Sponsors University Hospital, Antwerp
Indications
Therapies
Age Groups: adult | senior
Covered Countries BEL


No variant requirements are available.